Changing the future of Oncology.

About Sutro Biopharma

Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.


Precision protein engineering generates superior molecules


4 product candidates in the clinic as a result of research innovations


Premier collaborations with Bristol Myers Squibb, Merck, EMD Serono and Vaxcyte (formerly known as SutroVax)


Great people making excellence happen, every day! 


Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify optimal molecules designed for safety and potency.


Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways.


Recent News

Sutro Biopharma Announces Expansion of Leadership Team

- Nicole M. Chieffo, MBA, appointed to Vice President of Clinical Operations - Werner Rubas, Ph.D., appointed to Vice President of Preclinical Development SOUTH SAN FRANCISCO, Calif., Sept. 16, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug...

read more

Careers and Culture

At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference in the lives of patients, both as individuals and as part of a team.